학술논문
Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen
Document Type
Article
Author
Source
In Annals of Oncology August 2006 17(8):1205-1212
Subject
Language
ISSN
0923-7534